KR20170119871A - Zanthoxylum piperitum leaf extracts, fractions or compounds isolated therefrom with the effect of anti-inflammatory and analgesic - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for treating and preventing arthritis, which comprises a leaf extract of Zanthoxylum piperitum or a compound isolated therefrom, and more particularly to a pharmaceutical composition for treating and preventing arthritis comprising quercetin-3-O-alpha-L - Central and peripheral pain suppression and antiinflammatory effects of Laminocide (Quercitrin) and camphorol-3-O-alpha-L-Laminoside (Afzelin) , And the improvement effect of arthritis based on this was confirmed. Accordingly, the present invention relates to a composition for treating and preventing arthritis based on the effect of improving pain and inflammation, a compound of papaya leaf extract and a compound isolated therefrom, and a process capable of including these components under optimal conditions.
In other words, the extracts of papaya leaf, aquaticin and afzelin according to the present invention suppress pain, inflammation and arthritis both in pain induction animal model, inflammation induction model and arthritis induction model, and excellent expression and inhibition And can be used as a pharmaceutical composition highly effective for the treatment of arthritis based on pain and inflammation.

Description

FIELD OF THE INVENTION [0001] The present invention relates to a herb extract, its fractions or active compounds isolated therefrom, which are effective for anti-inflammation and analgesia. [0002] Zanthoxylum piperitum leaf extracts, fractions or compounds isolated therefrom with the effect of anti-inflammatory and analgesic

The present invention relates to an anti-inflammatory and analgesic composition comprising Zanthoxylum piperitum leaf extract, fractions thereof or compounds isolated therefrom.

Pain can be divided into primary pain with an immediate response to stimuli and secondary pain with a gradual feeling. This pain is detected through the receptors distributed in the skin or tissues. When receptors that are mainly responsible for physical stimulation, heat stimulation and chemical stimulation receive stimulation, they are transmitted to the central nervous system and feel pain. Unlike other senses, these pain become more sensitive as they persist, and the sensory response becomes even higher with weak pain. Existing analgesics that treat pain are classified as non-analgesic analgesics and narcotic analgesics. Drug analgesics include codeine, morphine, fentanyl, etc. Non-analgesic analgesics include acetaminophen, aspirin, ibuprofen, naproxen, Pen and so on. Non-analgesic analgesics inhibit the production of prostaglandins mainly from arachidonic acid, and have therapeutic effects on pain, arthritis, and pain associated with general pain and inflammation, and thus they are used as analgesic and anti-inflammatory agents. Most commonly used non-analgesic analgesics are classified as non-steroidal anti-inflammatory analgesics (NSAIDs), which exhibit analgesic, antipyretic, and anti-inflammatory effects by inhibiting acetaminophen and prostaglandins, which generally exhibit analgesic and antipyretic effects. Drugs such as acetaminophen are recommended to be used primarily in patients with osteoarthritis without inflammation because of the low side effects of gastrointestinal tracts in the guidelines of the American Rheumatology Society. Nonsteroidal anti-inflammatory analgesics are usually accompanied by inflammation Although it is recommended to use it in one arthritis, these nonsteroidal drugs should be taken with caution because they may cause side effects such as gastric ulcer and digestive tract hemorrhage.

Inflammatory reactions are caused by various stimuli such as infectious substances, ischemia, antigen-antibody reactions, heat or scars, and symptoms such as erythema, edema, tenderness and pain. This inflammatory response is a change that occurs to restore damaged tissue, which occurs in three stages mediated by different mechanisms. First, acute stage characterized by local vasodilatation and increased capillary permeability. Second, subacute stage characterized by leukocyte and phagocytic cell infiltration. Third, chronic stage where tissue degeneration and fibrosis occur. Other mechanisms are involved in the inflammatory process. Various biochemical phenomena are involved in the cause of inflammation in vivo. In particular, enzymes involved in biosynthesis of prostaglandins and Nitric Oxide Synthase (NOS), an enzyme that generates nitric oxide (NO), play an important role in mediating the inflammatory response. Drugs that can be used for inflammation include drugs that can inhibit inflammatory cell formation and exudation, and medications that can reduce the secretion of mediators of inflammation. Currently, drugs used for inflammation can be divided into the above-mentioned nonsteroidal drugs and steroidal drugs, and nonsteroidal drugs are widely used as analgesic and antiinflammatory agents. Nonsteroidal anti-inflammatory drugs (NSAIDs), which are commonly used as anti-inflammatory analgesics, inhibit the synthesis of prostaglandins in vivo and exhibit anti-inflammatory effects, but their action points are cyclooxygenase-1 (COX-1) and cyclooxygenase Genesis-2 (COX-2) is all that is involved and can cause side effects. In other words, COX-1 regulates the amount of prostaglandins involved in maintenance of blood flow, differentiation of cells, production of mucus and bicarbonate in each tissue, and inhibition of COX-1 activity by NSAIDs, resulting in adverse effects of gastrointestinal tract and kidney, Lt; / RTI > On the other hand, COX-2 is mainly found in the brain and kidney, and particularly in inflammatory sites, it is required to develop an anti-inflammatory agent that selectively inhibits COX-2.

Arthritis refers to the inflammatory changes of the joints. Symptoms of arthritis include tenderness in the joints, swelling, and thus the range of motion of the joints. Arthritis is largely classified into degenerative arthritis and rheumatoid arthritis. Unlike degenerative arthritis, where degenerative changes occur as cartilage disappeared as the age progresses, cartilage disappeared, and joint deformation was observed. Rheumatoid arthritis is the most common chronic inflammatory arthritis. It occurs mainly in the forties and causes heart disease, And it is expected that the incidence will increase further due to social impacts due to aging and economic growth. Rheumatoid arthritis is a systemic disease that causes chronic inflammation in the synovial membrane and surrounding soft tissues, which mainly surrounds the joints. It occurs in about 1% of the adult population, and the cause of the disease is not yet clear.

Prostaglandins are various inflammatory mediators in arthritis. Currently, aspirin, NSAIDs, etc. are used to inhibit the production of prostaglandins. As mentioned above, arachidonic acid is degraded by cyclooxygenase and converted to prostaglandin. Cyclooxygenase, which exists in two forms of COX-1 and COX-2, is present in various cells, but COX Compared to -1, COX-2 is expressed only in inflammatory cells. Therefore, inhibition of COX-2 and inhibition of the production of prostaglandins are important for the development of anti-inflammatory analgesics, particularly arthritis drugs.

On the other hand, Zanthoxylum piperitum is a deciduous shrub of hornblende, usually used as a spice and a medicine, and seeds, young leaves, trees and stems are also used for various purposes. Chowdhury fruit is used as a detox, insect repellent, and analgesic in oriental medicine. It is mainly distributed in Korea, Japan and China.

A number of patents have been published concerning Zanthoxylum piperitum . (Refer to Patent Documents 1 to 4) In the conventional invention, studies have been made mainly on fruit husks, roots, and woody parts of chickpea, and extracts thereof have been used as antibacterial, antiviral, insect, anticancer, antiinflammatory, , Diabetes, osteoporosis, and skin whitening.

However, none of the published literatures discloses that leaf extract of Zanthoxylum piperitum is effective in improving pain and arthritis,

In particular, the leaf extract of Chamaecyparis obtusa contains quercetin-3-O-alpha-L-rhamnoside and camphorol-3-O-alpha-L-lumnoside as indicators and active compounds, It is different from the extracts of fruit skin, roots and woody parts. In addition, there is no disclosure in the literature that quercetin-3-O-alpha-L-rhamnoside or camphorol-3-O-alpha-L-lamboside is effective for improving analgesia and inflammation,

Korean Patent No. 10-0314545 " Antimicrobial Substances Separated from Early Foliage Trees & Korean Patent No. 10-0666299 discloses an anticoronivirus composition containing a plant extract of the genus Chrysanthemum, Korean Patent No. 10-0883992 discloses a composition for prevention and treatment of a cardiovascular system disease comprising a herbal extract or a compound isolated therefrom, Korean Patent No. 10-1182824 discloses a method for producing an antiallergic composition containing a chopped fruit extract or a glycoprotein isolated therefrom,

Accordingly, the inventors of the present invention have searched for a natural substance which is more effective than conventional anti-inflammatory analgesic-based arthritic drugs and has little toxicity and side effects. As a result, it has been found that the extract of P. japonica, its fractions, The present inventors have completed the present invention by confirming that they exhibit excellent activity in an induction animal model, an inflammation induction model and an arthritis induction model. In particular, the leaf extract of Zanthoxylum piperitum has remarkable differences in contained components compared to Zanthoxylum schinifolium extract and has excellent antinociceptive ability, thus securing the inventive step of the present invention. [Reference example of the following examples]

Accordingly, it is an object of the present invention to provide a pharmaceutical composition for treating or preventing inflammation or pain, comprising the extract of P. falciparum, fractions thereof, or an active compound isolated therefrom as an active ingredient.

It is also an object of the present invention to provide a health food composition for improving inflammation or pain, comprising a papaya leaf extract, a fraction thereof or an active compound isolated therefrom as an active ingredient.

It is also an object of the present invention to provide a method for separating an active compound from a papaya leaf.

In order to solve the above-mentioned problems, the present invention relates to a herbal extract which is obtained by extracting Zanthoxylum piperitum leaves with at least one solvent selected from the group consisting of C _1-4 alcohol and C _1-4 alcohol aqueous solution, -3-O-alpha-L-rhamnoside or camphorol-3-O-alpha-L-lamboside represented by the following formula 2 or a mixture thereof as an active ingredient Lt; / RTI >

[Chemical Formula 1]

(2)

Another aspect of the present invention is to provide a pharmaceutical composition for the treatment and prevention of inflammation or pain containing the ethyl acetate fraction obtained by extracting the above-mentioned Zanthoxylum piperitum extract with ethyl acetate.

Another aspect of the present invention is a pharmaceutical composition comprising (A) quercetin-3-O-alpha-L-lambsoside, (B) camperol-3-O- alpha-L-lambsoside, (C) 4'- (D) 2,4-di- tert -butylphenol, and (E) 1,2-benzene dicarboxylic acid is contained in the pharmaceutical composition for treating or preventing inflammation or pain .

Another embodiment of the present invention is a papaya extract obtained by extracting Zanthoxylum piperitum leaves with at least one solvent selected from the group consisting of C _1-4 alcohol and C _1-4 alcohol aqueous solution. The extract of Quercetin-3 -O-alpha-L-rhamnoside or camphorol-3-O-alpha-L-lambsoside represented by the above formula (2) or a mixture thereof is contained as an active ingredient. do.

Another aspect of the present invention provides a health food composition for improving inflammation or pain containing an ethyl acetate fraction obtained by extracting Zanthoxylum piperitum extract with ethyl acetate.

Another aspect of the present invention is a pharmaceutical composition comprising (A) quercetin-3-O-alpha-L-lambsoside, (B) camperol-3-O- alpha-L-lambsoside, (C) 4'- Acetophenone, (D) 2,4-di- tert -butylphenol, and (E) 1,2-benzenedicarboxylic acid. to provide.

Further, another aspect of the present invention is a method for separating an active compound from Zanthoxylum piperitum ,

I) extracting a leaf of Zanthoxylum piperitum with at least one extraction solvent selected from the group consisting of C _1-4 alcohol and C _1-4 alcohol aqueous solution to obtain an alcoholic extract;

Ii) suspending the alcohol extract in water, and then fractionating the mixture with normal hexane, dichloromethane, ethyl acetate and normal butanol to obtain an ethyl acetate fraction; And

Iii) The ethyl acetate fraction was subjected to silica gel column chromatography and medium pressure chromatography (MPLC) to obtain quercetin-3-O-alpha-L-rhamnoside represented by Formula 1 or camphor- -O-alpha-L-rhamnoside, respectively; To isolate the active compound.

The present invention provides a Zanthoxylum piperitum leaf extract, a fraction thereof or an active compound isolated therefrom, wherein quercetin-3-O-alpha-L-lambsoside and / or camphorol-3-O- Lymphocytes exhibited excellent therapeutic efficacy in pain-induced animal models, inflammation-inducing models, or arthritis-inducing model experiments.

Accordingly, Zanthoxylum piperitum leaf extract, its fractions or active compounds isolated therefrom can be used as an effective ingredient in medicines or health foods for the treatment, prevention or amelioration of inflammatory diseases or pain diseases.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a process drawing showing the process of obtaining a solvent fraction and an active compound from an extract of P. falciparum; FIG.
2 is a GC-MS spectrum of (A) ZPE6A and (B) ZPE6C fractions.
FIG. 3 is a graph showing a pain-inhibiting effect on 4'-hydroxyacetophenone, 2,4-di- tert -butylphenol and 1,2-benzenedicarboxylic acid isolated from ZPE6A or ZPE6C fractions.
Fig. 4 is a graph showing the pain-inhibiting effect of the extract of P. falciparum on the basis of (A) the Tail avoidance reaction test method, (B) the hot plate test method, and (C) the formalin test method.
FIG. 5 is a graph showing the BDNF expression pattern measured by BV-2 microsomal cells of P. japonicus leaf extract using enzyme immunoassay.
FIG. 6 shows the inhibitory effect of the inflammatory index factors iNOS, COX-2, TNF-α, IL-1β and IL-6 on the extract of P. japonica leaf by the reverse transcription-PCR method and the immunoblotting method (A) Graph.
FIG. 7 shows the anti-inflammatory effect of the extract of P. falciparum in the subchronic ear edema model.
FIG. 8 is a 3D image showing the effect of treating the rheumatoid arthritis of the extract of P. haploi obtained in the collagen-induced rheumatoid arthritis model (CIA).
FIG. 9 is a H & E staining image showing the effect of treating the osteoarthritis of the extract of P. hawk extract in a collagenase-induced osteoarthritis model.
10 shows the results of (A) MMP-2, (B), (B) and (B) for each of the extracts of quercetin-3-O-alpha-L-lambsoside and camphorol- ) MMP-3, (C) TIMP-1 and (D) TIMP-2.
11 is a graph showing the effect of K + opening and closing control protein (KCNJ6) after treating papaya leaf extract, quercetin-3-O-alpha-L-lamboside or camphorol-3-O- Of the present invention.
12 is a graph showing the measurement of potassium (K ⁺ ) current density in BV-2 microcyst cells.
Figure 13 shows the effect of IFN-y on NK cells after collagen-induced animal model (CIA) papaya leaf extract, quercetin-3-O-alpha-L-lambsoside and camphorol-3-O- And the amount of expression was measured.
14 is a graph showing the effect of the extracts of papaya leaf in collagen-induced animal model (CIA), quercetin-3-O-alpha-L-lambsoside and camphorol-3-O-alpha-L- (A: IL-6, B: IL-17, C: IL-21 and D: IL-22).

 Hereinafter, the present invention will be described in detail.

The present invention relates to a pharmaceutical composition comprising Zanthoxylum piperitum leaf extract, a solvent fraction obtained by extracting the extract with an organic solvent, quercetin-3-O-alpha-L-lambsoside isolated therefrom and camphorol-3-O- Prevention, and treatment of inflammation or pain containing the active ingredient as an active ingredient.

In addition, the present invention features a series of methods for separating extracts, fractions and active compounds from Zanthoxylum piperitum , and specifically includes the following steps:

I) extracting a leaf of Zanthoxylum piperitum with at least one extraction solvent selected from the group consisting of C _1-4 alcohol and C _1-4 alcohol aqueous solution to obtain an alcoholic extract;

Ii) suspending the alcohol extract in water, and then fractionating the mixture with normal hexane, dichloromethane, ethyl acetate and normal butanol to obtain an ethyl acetate fraction; And

Iii) The ethyl acetate fraction was subjected to silica gel column chromatography and medium pressure chromatography (MPLC) to obtain quercetin-3-O-alpha-L-rhamnoside represented by the following formula 1 or camphor- -O-alpha-L-rhamnoside, respectively.

The method for separating the extract, the solvent fraction or the active compound from the papaya leaf will be described in more detail with reference to the process drawing of FIG.

Step i) is a step of obtaining a Zanthoxylum piperitum leaf extract.

Chamaecypally also can utilize whole plants such as leaves, stems, branches, roots. According to the results of the present inventors' experiments, there was a remarkable difference in pain control ability at each part of the plant. The extract of Pepper leaf showed excellent inhibition of pain by about 700% compared to root extract, and about 26% And it was confirmed that the pain suppression rate was excellent. [0052] [52] [52] [52] Hereinafter, the present invention will be described in detail.

The leaves of the mulberry leaves were cleaned with water, dried and shrunk. And extracted by immersing in at least one extraction solvent selected from the group consisting of C _1-4 alcohol and C _1-4 alcohol aqueous solution. The extraction solvent may be selected from methanol, ethanol, isopropanol, propanol, butanol and aqueous solutions thereof. Preferably, ethanol or ethanol aqueous solution is used. More preferably, ethanol aqueous solution having a concentration of 90 to 95% will be. The amount of the extraction solvent is preferably 1: 1 to 30 times by weight, more preferably 1:10 to 20 times by weight, based on the dry weight of the papaya leaf, and the amount of the extraction solvent is limited by the present invention no. The extraction temperature may be in the range of from room temperature to the reflux temperature of the extraction solvent, and specifically, it may be extracted at a temperature of 20 to 80 ° C. The extraction time is preferably 1 to 10 days, but is not limited thereto. The number of times of extraction may be one or more times, but since the yield of the active ingredient is remarkably reduced as the extraction continues, it may not be economical to repeat the extraction more than 5 times. Therefore, the extraction is preferably repeated two to five times Do.

The extraction method is a method commonly known in the art, for example, a method using an extraction device such as a supercritical extraction, a subcritical extraction, a high-temperature extraction, a high-pressure extraction or an ultrasonic extraction, or a method using an adsorption resin containing XAD and HP- And the like can be used.

The extract is concentrated under reduced pressure using a vacuum rotary evaporator or the like to obtain an extract. The resulting extract may also be subjected to vacuum drying, vacuum drying, boiling drying, spray drying, room temperature drying, freeze drying, and the like, if necessary.

Step ii) is a step of extracting the herbal extract with an organic solvent to obtain an ethyl acetate fraction.

Specifically, among the fractions obtained by suspending the ethanolic extract of the chickpea leaves obtained in the step (i) in water and sequentially fractionating the fractions with normal hexane, dichloromethane, ethyl acetate and normal butanol, the ethyl acetate fraction having the highest activity ≪ / RTI > The above fraction can be obtained by repeating from 1 to 5 times, preferably 3 times, followed by fractionation and concentration under reduced pressure and drying, but the present invention is not limited thereto.

Step iii) is a step of isolating the active compound by subjecting the ethyl acetate fraction to silica gel column chromatography and medium pressure chromatography (MPLC).

Specifically, the ethyl acetate fraction obtained in the step (ii) is loaded on a glass column (5 x 50 cm) filled with silica beads, and subjected to silica gel column chromatography. At this time, a mixed solution of ethyl acetate and methanol was used as an eluent, and elution was carried out by changing the volume ratio of ethyl acetate / methanol from 90/10 to 60/40. Seven fractions were obtained by the above silica gel column chromatography. The obtained fractions were named ZPE1, ZPE2, ZPE3, ZPE4, ZPE5, ZPE6 and ZPE7. Among the seven fractions obtained by performing the above silica gel column chromatography, ZPE6 showed the most excellent activity, and the fraction ZPE6 was selected and then subjected to MPLC (medium pressure chromatography).

The selected fraction ZPE6 is loaded on a sephadex LH-20 column and subjected to medium pressure chromatography (MPLC). At this time, the eluent is eluted with methanol alone solution. As a result of the MPLC, three small fractions were obtained. The obtained fractions were named ZPE6A, ZPE6B and ZPE6C. Among the three small fractions obtained by the above-mentioned MPLC, ZPE6B exhibited the most excellent activity, and the active compound was isolated by selecting the small fraction ZPE6B.

To separate the active compound from the small fraction ZPE6B, high performance liquid chromatography (HPLC) is carried out using a reversed phase column packed with octadecylated silica. At this time, a mixed solution of methanol and water is used as the eluent, and a 50% methanol aqueous solution containing an equal amount of methanol and water is preferably used.

The active compound separated through HPLC was analyzed by nuclear magnetic resonance spectroscopy to determine the presence of quercetin-3-O-alpha-L-luramnoside (quercitrin) represented by the following formula (1) -3-O-alpha-L-lamboside (Afzelin).

The active component 1 and the active component 2 isolated from the above were identified by nuclear magnetic resonance spectroscopy.

[Chemical Formula 1]

(2)

(1) a Zanthoxylum piperitum leaf extract obtained through the above separation method, a solvent fraction obtained by extracting the extract with an organic solvent, quercetin-3-O-alpha-L-lamboside -O-alpha-L-lamboside (Formula 2) showed significant results in the pain-induced animal model, the inflammation-inducing animal model, and the arthritis-induced animal model. Accordingly, the compound represented by the general formula (1) or (2) as an active compound isolated from a papaya leaf extract, a fraction thereof and / or an active ingredient thereof can be used as a pharmaceutical composition or a health food composition for the purpose of improving, ≪ / RTI >

The pharmaceutical composition according to the present invention may comprise as an active ingredient an extract of P. falciparum, a fraction thereof and / or an active compound isolated therefrom, and the effective ingredient may be contained in an amount of 0.1 to 50% by weight based on the total weight of the composition, The present invention is not limited thereto.

The pharmaceutical composition of the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to a conventional method. Accordingly, the pharmaceutical composition of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of medicaments.

Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methylcellulose, hydroxymethylcellulose, microcrystalline cellulose, silicified microcrystalline cellulose, povidone, crospovidone, croscarmellose sodium, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, Colloidal silicon dioxide, lactose, talc, magnesium stearate, colloidal stearyl magnesium, mineral oil, and the like.

 In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, troches, rosin, capsules and the like, which may contain at least one excipient such as lactose, saccharose, sorbitol , Mannitol, starch, amylopectin, cellulose, calcium carbonate, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, elixirs, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like are used in addition to water and liquid paraffin, May be included. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a suppository base, witepsol, macrogol, tween 61, cacao paper, laurin, glycerol gelatin and the like can be used. Parenteral administration may be by subcutaneous injection, intravenous injection, intramuscular injection or intra-thoracic injection.

The pharmaceutical composition of the present invention can be administered orally or parenterally. Any parenteral administration method can be used, and systemic administration or local administration is possible, but systemic administration is more preferable, and intravenous administration is most preferable.

The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and body weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the pharmaceutical composition of the present invention is preferably administered at a daily dose of 0.0001 to 1000 mg / kg, preferably 10 to 300 mg / kg (body weight). The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.

In addition, the health food composition according to the present invention contains the extract of P. japonica, fractions thereof and / or active compounds isolated therefrom as an active ingredient, and may be added to health supplements such as food, beverage, and the like.

There is no particular limitation on the kind of the food. Examples of foods to which the active ingredient can be added include dairy products including dairy products, meat, sausage, bread, biscuits, rice cakes, chocolates, snacks, confectionery, pizza, ramen noodles, other noodles, gums, ice cream, , Beverages, alcoholic beverages and vitamin complexes, dairy products, and dairy products, all of which include health functional foods in a conventional sense. The active ingredient may be added directly to the food or may be used together with other food or food ingredients, and may be suitably used according to conventional methods. The content of the active ingredient can be suitably determined according to its use purpose (for prevention or improvement). Generally, the active ingredient in the health food composition may be contained in an amount of 0.1 to 90% by weight. However, in the case of long-term intake intended for health and hygiene purposes or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

The beverage can be prepared using the health food composition of the present invention. There are no particular restrictions on the selection of other ingredients other than the active ingredient as a component to be contained in the beverage, and it may contain various flavors or natural carbohydrates as additional ingredients such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.

In addition, the health food composition of the present invention may contain various additives such as various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and aging agents (cheese, chocolate, etc.) Salts, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks and the like. It can also contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so important, but is generally selected in the range of 0.1 to 20% by weight in the health food composition of the present invention.

The present invention as described above is explained in more detail based on the following examples, but the present invention is not limited thereto.

[Example]

[Pain-inhibiting efficacy and anti-inflammatory efficacy measurement method]

The anti-pain and anti-inflammatory effects of the extracts, fractions or active compounds of the extracts of the present invention were measured by the following methods.

1. Method to confirm pain relieving efficacy

(1) analgesic effect by acetic acid induced pain model

Acetic acid-induced writhing syndrome test is an animal model for analgesic effects and is mainly used to test the efficacy of painkillers acting on the peripheral nervous system. Five-week-old ICR mice (Central Experimental Animals, Seoul) were purchased from the experimental animals. The animals were kept in a habitat maintained at 50% humidity and 24 ~ 26 ℃ for 1 week. Feed and water were supplied for free consumption. When 1.5% acetic acid is injected into the abdominal cavity of the mouse as irritants, it causes pain in the abdominal cavity and causes a writhing syndrome reaction such as twisting the body or stretching the hind legs. The analgesic effect was measured by oral administration of the test substance 60 minutes before the pain.

(2) Analgesic effect by tail avoidance test

Tail-flick test is mainly used to test the efficacy of analgesics acting on the central nervous system using acute pain models. The experimental materials were orally administered 30 minutes and 60 minutes before the pain, and the mice 'tail was placed on the hot plate and the tail evasion reaction was measured.

(3) Analgesic effect by hot plate test method

Hot plate test is a method used to search for painkillers acting on the central nervous system. Since the soles of the mouse are very sensitive to heat, when an unbearable heat is detected, the mouse is run, the soles are shrunk , Or licking. The test substance was orally administered 60 minutes before the pain, and the time (sec) from the time of contact with the hot plate to the time of shaving or licking the rear foot was measured.

(4) Analgesic effect by the formalin test method

The formalin test is mainly used to measure the analgesic effects of drugs on chronic pain models in which pain stimuli and responses are temporarily and persistently present. Formalin-induced pain responses undergo a one- and two-phase steps, which can be pharmacologically distinguishable. The experimental material and acetaminophen or aspirin, which is a positive control, were orally administered 60 minutes before the pain, 10% formalin was subcutaneously injected into the hind paw of the rats, and the number of behaviors for pain was measured every 3 minutes. The behavior of pain was divided into 1 phase (0 ~ 12 min) and 2 phase (24 ~ 39 min).

2. Anti-inflammatory efficacy confirmation method

(1) Enzyme-Linked ImmunoSorbent Assay

BDNF (brain derived neurotrophic factor) is a neurotrophic factor mainly present in the brain. It binds to receptors such as tropomycin-related kinase B (TrkB) and p75, and causes pain through interaction with them. In order to measure the expression pattern of BDNF by the test substance, the amount of BDNF expression in BV-2 microdissociated cells was examined using an ELISA kit (Uscn, china).

(2) reverse transcription-PCR method

The RNA was lysed using the TRIzol Reagent kit (Gibco BRL) according to the manufacturer's instructions. 1 μg of RNA was reverse transcribed with 10,000 U of reverse transcriptase and 0.5 g / L oli- (dT) 15 primer. 1 μL of the synthesized cDNA was amplified by PCR using iNOS, COX-2, TNF-α, IL-1β and IL-6 primers. The PCR product was isolated on 1% agarose gel and visualized with UV.

(2) Immunoblot analysis

The cell lysate was placed in 40 μL of buffer solution and stored at 4 ° C. for 30 minutes. Then, 30 μg of protein was classified by electrophoresis on 10% SDS-polyacrylamide gel. The protein was then transferred to the nitrocellulose membrane and blocked with skim milk for 1 hour. After washing three times for 10 minutes with TBST buffer solution, the primary antibody was treated. Cell membranes were stored with secondary antibody conjugated to HRP (horseradish peroxidase). Immunoreactive bands were detected by ECL fluorescence (enhanced chemiluminescence) reagents according to the manufacturer's instructions.

(4) Anti-inflammatory effect in subchronic ear edema model

12-O-tetradecanoyl-13-phorbol acetate (TPA). The experimental material was orally administered to a 5-week-old ICR mouse that had been subjected to a one-week purification process, and 1 μg / ear of TPA was applied to the right ear after 1 hour. This process was repeated for 3 days, and the thickness of the mouse ear was measured on the fourth day, and the weight per area of the ear tissue was measured.

[Manufacturing Example]

Production Example 1. Isolation of Extracts, Fractions and Active Compounds of Pepsi Leaf

The process of separating the extract, fraction and active compound from the leaf of a papaya leaf according to the process chart shown in Fig. 1 will be described below.

Zanthoxylum piperitum was obtained from the southern region of Korea. The leaves of the chestnut were washed, dried and shrunk. The leaves of the mulberry leaves were immersed in a 90% ethanol aqueous solution and extracted 2 to 5 times at room temperature. The extract was subjected to vacuum distillation to obtain an ethanol extract of papaya leaf.

68.8 g of ethanol extract of P. chinensis was suspended in 2 L of distilled water, and then fractionated with an equal amount of normal hexane, dichloromethane, ethyl acetate, normal butanol and water, and concentrated under reduced pressure to obtain respective solvent fractions. Each of the obtained solvent fractions was tested for anti-inflammatory and pain-inhibiting activity, and the ethyl acetate fraction showing the most excellent activity was selected.

The ethyl acetate fraction was loaded on a glass column (5 x 50 cm) filled with silica beads (silica beads) and subjected to silica gel column chromatography. At this time, a mixed solution of ethyl acetate and methanol was used as an eluent, and elution was carried out by changing the volume ratio of ethyl acetate / methanol from 90/10 to 60/40. Fraction ZPE6, 1.90 g; Fraction ZPE2, 0.32 g Fraction ZPE2, 0.30 g Fraction ZPE41, 1.13 g Fraction ZPE5, 0.54 g Fraction ZPE6, 1.90 g Fraction ZPE7, 1.90 g). The anti-inflammatory and pain-inhibiting effects of each of the seven fractions were confirmed, and the fraction ZPE6 showing the most excellent activity was selected.

The fraction ZPE6 was concentrated under reduced pressure, completely dried, and packed in a column of sephadex LH-20, and subjected to medium pressure chromatography (MPLC). At this time, the eluent was eluted with methanol alone solution. Three fractions (fraction ZPE6A, 24.7 mg; fraction ZPE6B, 416 mg; fraction ZPE6C, 85.4 mg) were obtained by performing the above intermediate pressure chromatography (MPLC). The anti-inflammatory and anti-inflammatory effects of each of the three small fractions were confirmed, and a small fraction of ZPE6B exhibiting the best activity was selected.

The small fraction ZPE6B was subjected to HPLC (eluent: methanol / water = 50/50) using a reversed phase column packed with octadecylsilica to classify active ingredient 1 and active ingredient 2.

The active component 1 and the active component 2 isolated from the above were identified by nuclear magnetic resonance spectroscopy.

Active ingredient 1 :

^{1 H-NMR (300 MHz,} DMSO- d 6) δ 0.9 (d, J = 6 Hz, CH 3), 5.2 (d, J = 1.5 Hz, H-1 "), 6.15 (d, J = 2.2 Hz , H-6), 6.36 ( d, J = 2.2 Hz, H-8), 6.95 (d, J = 8.2 Hz, H-5 '), 7.25 (dd, J = 2.2 Hz and J = 8.2 Hz, H -6 '), 7.35 (d, J = 2.2 Hz, H-2'); 13 C-NMR (75 MHz, DMSO- d 6) δ 17.5 (C-6 "), 70.0 (C-5"), (C-2), 71.1 (C-4), 93.6 (C-8), 98.6 (C-3 '), 115.1 (C-2'), 115.6 (C-5 '), 120.7 148.3 (C-4 '), 156.4 (C-2), 157.2 (C-9), 161.3 (C-

Based on the results of the above spectroscopic analysis, the active ingredient 1 was identified as quercetin-3-O-alpha-L-lamboside represented by the following formula (1). Spectrophotometric analysis of active ingredient 1 was in good agreement with the literature values of quercetin-3-O-alpha-L-lumnoside (quercitrin).

[Chemical Formula 1]

Active Ingredient 2 :

^{1 H-NMR (300 MHz,} DMSO- d 6) δ 0.9 (d, J = 6 Hz, CH 3), 5.29 (1H, d, J = 1.5 Hz, H-1 "), 6.21 (1H, d, J = 2.5 Hz, H-6 ), 6.42 (1H, d, J = 2.5 Hz, H-1 "), 6.21 (1H, d, J = 2.5 Hz, H-6), 6.42 (1H, d, J = 2.5 Hz, H-8) , 6.91 (2H, d, J = 8.4 Hz, H-3 'and H-5'), 7.74 (2H, d, J = 8.4 Hz, H-2 'and H-6 '); ^{13 C-NMR (75 MHz,} DMSO- d 6) δ 17.4 (C-6 "), 70.0 (C-5"), 70.2 (C-2 "), 70.6 (C-3"), 71.0 (C- (C-10), 115.3 (C-3 ', C-5'), 120.5 (C- 1), 130.6 (C-2 ', C-6'), 134.2 (C-3), 156.5 (C-9), 157.2 ), 164.3 (C-4), 177.7 (C-7)

Based on the results of the above spectroscopic analysis, the active ingredient 2 was identified as camphorol-3-O-alpha-L-rhamnoside represented by the following formula (2). Spectrophotometric analysis of active ingredient 2 was in good agreement with the literature values of camper roll-3-O-alpha-L-lambsoside (Afzelin).

(2)

Example 1: Preparation of pain-inhibiting effect of each region

The extracts according to Preparation Example 1 were used to prepare 90% ethanol extracts to prepare the extracts for inhibiting the pain of each of the leaves, young leaves, fruits, stems and roots. The pain relief efficacy of each extract was measured using acetic acid induced pain model, and the results are shown in Table 1 below.

The inhibitory effect of ethanol extracts on cow parts Cusp region Pain inhibition (%)
(100 mg / kg, po) leaf 91.6 Young branch 84.7 Fruit 72.8 stem 65.0 Root 11.8

According to the results shown in Table 1, there was a remarkable difference in the pain-suppressing effect of each part of the dandruff, and the efficacy of the leaf extract was the most excellent. Leaf extracts showed about 25.8% better inhibition of pain than fruit extracts.

Example 2. Preparation of pain-inhibiting effect by concentration of aqueous ethanol solution

The antioxidant activity of the extracts of P. falciparum was determined by the concentration of extract solution. That is, ethanol extracts of papaya leaf were obtained by the extraction method according to Preparation Example 1 using an ethanol aqueous solution having a concentration of 0 to 100%. For each extract, acetic acid-induced pain model was used to measure the pain-inhibiting effect, and the results are shown in Table 2 below.

The inhibition of pain in the extract of P. japonicus by the concentration of aqueous ethanol solution Concentration (%) of aqueous ethanol solution Pain inhibition (%)
(100 mg / kg, po) 0 (water) 30.8 10 31.8 20 36.4 30 38.3 40 40.2 50 41.1 60 43.3 70 55.1 75 55.1 80 57.9 85 71.0 90 91.6 95 90.1 100 85.4

According to the results shown in Table 2 above, as the concentration of aqueous ethanol solution used for extraction was increased, the inhibition rate of the papaya leaf extract was increased. From the viewpoint of the pain-inhibiting effect, the concentration of the aqueous ethanol solution is preferably 50% or more, more preferably 90% or more of the aqueous ethanol solution.

Example 3: Pain-inhibiting effect of fractions of Leaf leaf

The solvent fractions obtained by fractionating the ethanol extract of P. chinensis according to Preparation Example 1 were prepared for the pain-inhibiting effect. That is, the fractions obtained by successively fractionating the 90% ethanol extract with normal hexane, dichloromethane, ethyl acetate, normal butanol and water were measured for the pain-inhibiting effect using the acetic acid-induced pain model. The results are shown in Table 3 .

Pain inhibition rate of solvent fraction Fraction Pain inhibition (%)
(50 mg / kg, po) N-hexane fraction 24 Dichloromethane fraction 48 Ethyl acetate fraction 82 Normal butanol fraction 27 Water fraction 42

According to the above Table 3, the ethyl acetate fraction showed the most excellent pain suppressing effect.

Example 4. Anti-pain control effect of ethyl acetate small fraction

The seven fractions obtained by silica gel column chromatography on ethyl acetate fractions according to Preparation Example 1 were prepared for pain control efficacy. That is, the pain-inhibiting effect was measured using an acetic acid-induced pain model for small fractions classified as ZPE1, ZPE2, ZPE3, ZPE4, ZPE5, ZPE6 and ZPE7, and the results are shown in Table 4 below.

Percent inhibition of pain in ethyl acetate small fraction A small fraction of EtOAc Pain inhibition (%)
(100 mg / kg, po) ZPE 1 18.2 ZPE 2 30.1 ZPE 3 31.6 ZPE 4 59.5 ZPE 5 71.3 ZPE 6 82.9 ZPE 7 48.3

According to Table 4, the sixth small fraction (ZPE6) among the ethyl acetate small fractions showed the most excellent pain suppressing effect.

Example 5: Anti-pain effect of ZPE6 small fraction

The three sub-fractions obtained by separating the ZPE6 fraction obtained in Preparation Example 1 by medium pressure chromatography (MPLC) were prepared for pain control efficacy. That is, for the small fractions classified as ZPE6A, ZPE6B, and ZPE6C, the pain-inhibiting effect was measured using an acetic acid-induced pain model, and the results are shown in Table 5 below.

Percent inhibition of pain in ZPE6 small fraction ZPE6 small fraction Pain inhibition (%)
(100 mg / kg, po) ZPE6A 64.1 ZPE6B 79.4 ZPE6C 66.2

According to the above Table 5, the second small fraction (ZPE6B) among the small fractions of ZPE6 showed the most excellent pain suppressing effect.

Example 6: Pain inhibiting effect of active ingredient isolated from ZPE6B small fraction

In the ZPE6B fraction obtained in Preparation Example 1, the two active ingredients quercetin-3-O-alpha-L-quercitrin and camphorol-3-O-alpha-L - Laminocyte (Afzelin) was isolated, and the pain control effect was prepared. That is, the acetic acid-induced pain model was applied to quercetin-3-O-alpha-L-lumnoside (quercitrin) and camphorol-3-O- alpha-L-lamboside (afzelin) The inhibition efficacy was measured and the results are shown in Table 6 below.

Pain reduction rate of active ingredient Active ingredient Pain inhibition (%)
(50 mg / kg, po) ZPE6B 76.4 Aquitin 69.2 Afzelin 93.6

According to the above Table 6, the active ingredient quercetin-3-O-alpha-L-lumnoside (quercitrin) and camphorol-3-O-alpha-L- Jelin, and Afzelin) showed excellent pain suppression rates in the acetic acid-induced pain model. In particular, afzelin isolated from the small fraction, ZPE6B, excellently superior in pain inhibition.

According to the results shown in Table 6 above, ZPE6B was superior in analgesic effect among the three small fractions separated by the medium pressure chromatography (MPLC) in Production Example 1, and ZPE6B contained a large amount of compounds having excellent pain inhibiting activity such as afzelin It seems that there is a reason.

Example 7. GC-MS analysis of small fractions of ZPE6A and ZPE6C

ZPE6A and ZPE6C showed lower analgesic effect than ZPE6B among the three small fractions isolated in Preparation Example 1, but the analgesic activity was superior to the other fractions or the control group. Table 7 below shows the results of GC-MS analysis for analyzing the active components contained in the small fractions ZPE6A and ZPE6C.

peak
number compound ZPE6A ZPE6C RT Area
(%) RT Area
(%) One 2,4-di- tert -butylphenol 14.540 26.69 14.540 12.09 2 Eiko Mountain 15.974 3.99 14.288 3.67 3 Methyl myristate 17.977 4.00 17.978 4.84 4 Methyl palmitate 20.933 32.09 20.934 31.05 5 1,2-benzenedicarboxylic acid 21.514 6.99 21.514 9.53 6 Methyl stearate 23.638 10.78 23.649 9.86 7 1,2-benzenedicarboxylic acid dipropyl ester 28.674 15.47 28.674 17.85 8 4'-hydroxyacetophenone N / D N / D 12.514 5.62 9 Nonadecan N / D N / D 15.974 5.49

According to the results of the GC-MS analysis of Table 7, among the ZPE6A or ZPE6C fractions, 4'-hydroxyacetophenone represented by the following formula 3, 2,4-di- tert -butylphenol represented by the following formula 4, Benzene dicarboxylic acid represented by the formula (5).

In addition, pain relieving efficacy was measured using 4'-hydroxyacetophenone, 2,4-di- tert -butylphenol and 1,2-benzenedicarboxylic acid isolated from the ZPE6A or ZPE6C fractions using acetic acid induced pain model , And the results are shown in Fig.

3 shows that 4'-hydroxyacetophenone, 2,4-di- tert -butylphenol and 1,2-benzene dicarboxylic acid are also excellent in pain control effect. Among them, 4'- Acetophenone can be confirmed to be excellent in pain control efficacy.

Example 8: Comparison of the content of active compound with extraction conditions

In the process of obtaining the extract of P. japonicus according to Preparation Example 1, each extract was obtained while changing the extraction solvent and temperature conditions. For each extract, the content of active compounds (aquitinel, arthritis) was analyzed by HPLC, and the pain inhibition rate was measured using an acetic acid-induced pain model. The results are shown in Table 8 below.

[Extraction condition]

Condition 1) 90% ethanol extract (unheated),

Condition 2) 90% ethanol extract (heating),

Condition 3) A substance obtained by centrifuging a 90% ethanol extract using a heating method to remove the emulsion.

Condition 4) A fraction obtained by fractionating 90% ethanol extract with dichloromethane,

Condition 5) The residue except for the fraction obtained by fractionating the 90% ethanol extract with dichloromethane,

Condition 6) Normal hexane extract,

Condition 7) The ethanol extract obtained by extracting the normal hexane extract with 90% ethanol,

Conditions 8) Dichloromethane extract,

Conditions 9) Dichloromethane Extracts were extracted with 90% ethanol.

The inhibition rate of the extract and the content of the active compound extraction
Condition Name of sample yield
(%) Pain inhibition (%)
(50 mg / kg, po) The active compound (area%, RT 25 min) Aquitin Afzelin Condition 1 EtOH Extract - Unheated 5.1 45.5 36.47 12.85 Condition 2 EtOH Extract - Heating 6.8 75.2 56.44 4.68 Condition 3 Condition 2 The emulsifying agent of the extract 5.7 74.5 58.02 4.05 Condition 4 Ethanol extract
CH ₂ Cl ₂ fractions 2.2 41.8 2.60 7.88 Condition 5 Residue in condition 4 3.6 60 66.47 15.36 Condition 6 N-hexane extract 1.1 76.4 0.41 4.81 Condition 7 Condition 6 EtOH extract of extract 5.1 0 49.5 14.33 Condition 8 CH ₂ Cl ₂ extract 1.7 81.8 0.37 6.01 Condition 9 Condition 8 EtOH extract of the extract 4.5 23.6 59.49 15.91

According to the above Table 8, it can be seen that the content of the active compound may be varied depending on the extraction conditions. As suggested by the present invention, the alcohol extract obtained by the conditions 1, 2, and 3 effectively inhibited the pain suppression rate and the content of the active compound.

Example 9. Analgesic effect of the leaf extract

The analgesic efficacy of the 90% ethanol extract of the chickpea leaf obtained in Preparation Example 1 was measured using various animal models.

Fig. 4 shows the results of measuring the analgesic effect of the papaya leaf extract by (A) the Tail Avoidance Test, (B) the Hot Plate Test, and (C) the formalin test. 4, it can be seen that the extract of P. falciparum according to the present invention is excellent in anti-analgesic effect.

Example 10 Anti-inflammatory Effect

The anti-inflammatory activity of the 95% ethanol extract of P. japonicus leaf obtained in Preparation Example 1 was measured by enzyme immunoassay, reverse transcription-PCR, and immunoblotting.

FIG. 5 shows the results of an examination of the amount of BDNF expression at 0, 25, 50, and 100 占 퐂 / mL of the extract of P. japonicus by immunoassay. The amount of BDNF expression decreased with increasing the throughput of the leaf extract. As a result, it was confirmed that the extract showed the highest anti - inflammatory activity at 100 ㎍ / mL.

Fig. 6 shows the results of measuring the inhibitory effect of the inflammatory index factors measured by (A) reverse transcription-PCR and (B) immunoblotting. FIG. 6 shows that the inhibition of the expression of inflammatory markers of iNOS, COX-2, TNF-α, IL-1β and IL-6 overexpressed by lipopolysaccharide (LPS) .

Example 11 Anti-Inflammatory Effect of Chow Leaf Extract on Subchronic Ear Edema Model

FIG. 7 shows the result of measuring the anti-inflammatory effect after orally administered at 25, 50, and 100 mg / kg of P. japonicus leaf extract in a mouse model induced by TPA.

The thickness and weight of ears were significantly increased by TPA, and it was confirmed that the thickness and weight of ear edema were effectively reduced by oral administration of papaya leaf extract. The anti - inflammatory effect tended to increase as the throughput of the extract was increased. When the results of immunohistochemical analysis of immunohistochemistry were examined, it can be confirmed that the papaya leaf extract effectively inhibited the infiltration of immune cells into tissues.

Example 12: Treatment effect of raspberry leaf extract on rheumatoid arthritis

The anti-rheumatic efficacy of each test substance was measured in an animal model of arthritis induced by collagen as one of the methods for evaluating the efficacy of rheumatoid arthritis treatment. Five-week-old DBA / 1J mice (Central Experimental Animals, Seoul) were purchased and cultivated in a farm maintained at 50% humidity and 24-26 ℃ for 1 week. Feed and water were fed for free consumption . To induce arthritis, type II collagen and complete Freund's adjuvant (CFA) were mixed to obtain an emulsion. 200 μL of emulsion was injected subcutaneously to the lower part of the tail 2 to 3 cm away from the body of the DBA / 1J mouse. After 21 days of primary antigen exposure, the same amount of emulsion was injected into the lower part of the tail Lt; RTI ID = 0.0 > 150 < / RTI > From day 22 of the initial antigen exposure, dexamethasone was orally administered at a dose of 1 mg / kg for the positive control group, and rheumatoid arthritis lesion was graded by oral administration at 100 mg / kg for 3 weeks, The clinical efficacy of arthritis was evaluated by clinical score.

The visual clinical scores measured by the above method are shown in Table 9 below.

Visual Clinical Score in Collagen-Induced Arthritis Model group number Right front leg Left foreleg Right hind leg Left hind leg Total score Control group One 3 3 One 4 11 2 3 3 4 4 14 3 3 3 2 One 9 4 3 3 4 4 14 5 3 3 3 2 11 6 3 One 4 4 12 Positive control group One One 2 One One 5 2 One One One 2 5 3 3 3 One One 8 4 3 2 One One 7 5 2 One One 2 6 6 2 2 One One 6 7 2 3 One One 7 Extract of mulberry extract One One One One 2 5 2 One One One 3 6 3 One One 3 3 8 4 One 2 One 3 7 5 2 One 4 2 9 6 3 3 2 4 12 7 One One 4 3 9

As shown in Table 9, the average score of the control group was 11.8, whereas the average score of the group treated with the extract of P. japonicus was 8, which is very low. Considering that the average score of the dexamethasone-treated group, which is a positive control, is 6.3, the extract of P. japonica is effective as a treatment for rheumatoid arthritis.

8 shows the result of analyzing an ankle joint of a hind leg on a 3D image using a micro-CT. In the control group, the shape of the bone in the joints changes irregularly, indicating that bone destruction due to inflammation is progressing considerably. On the contrary, it was observed that the bone destruction or deformation was remarkably decreased in the 3D-image of the group treated with the extract of P. falciparum, and the efficacy of treating arthritis was almost the same even in the dexamethasone group.

Example 13. Therapeutic effect in osteoarthritis-induced animal models

One of the methods for evaluating the efficacy of osteoarthritis treatment was to measure the improving effect of test substances on collagenase-induced arthritis. Five-week-old SD rats (Central laboratory animals, Seoul) were purchased from the experimental animals. The animals were kept in a habitat maintained at 50% humidity and 24 ~ 26 ℃ for 1 week. Feed and water were supplied for free consumption. To induce arthritis, 4 mg / mL type 2 collagenase was injected into the right articular capsule of the rat in 0.05 mL (0 day) and started 4 days later. Celecoxib (10 mg / kg) and papaya leaf extract (300 mg / kg) were orally administered once a day to the normal control group treated with distilled water and the osteoarthritis control group and the positive control group after collagenase injection. The results of histopathological examination of the joints at 7 weeks were shown in FIG.

According to FIG. 9, the area of inflammation was significantly reduced after 7 weeks in the extract of P. falciparum extract, and it was confirmed that the effect was excellent in comparison with the group treated with celecoxib.

Example 14. Therapeutic effect in osteoarthritis-induced animal models

Osteoarthritis occurs as an abnormality in cartilage cell metabolism, and the enzymes involved in cartilage damage are typically matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) . An animal model of osteoarthritis induced by the administration of MIA (Monosodium Iodoacetate) induces cartilage damage of the knee joint by interfering with the metabolism of chondrocytes, and symptoms similar to osteoarthritis appear.

FIG. 10 shows the results of biochemical markers changes of MMP-2, MMP-3, TIMP-1 and TIMP-2 in an animal model of osteoarthritis induced by MIA. According to FIG. 10, it can be seen that the extract of P. japonica and the active compounds (quasitrin, arthritis) have excellent therapeutic effect on osteoarthritis, and in particular, afzelin has excellent therapeutic effect on osteoarthritis.

Example 15. Identification of the mechanism of action of pain suppressant extracts and active substances

In order to investigate the mechanism of inflammation and pain suppression such as arthritis, the PCR arrangement was observed using BV-2 cells, a brain microsoprotein. Experimental groups were divided into chestnut leaf extract and active compounds quercitrin and afzelin.

FIG. 11 is a graph showing the degree of expression of the protein KCNJ6 after treatment with papaya leaf extract, quercitrin, and afzelin in brain microsoprotein BV-2 cells. 12 is a graph showing the measurement of potassium (K ⁺ ) current density in BV-2 cells as brain microsoprobes.

The results of FIGS. 11 and 12 show that the K + current density tends to increase as the degree of expression of the K + regulatory protein KCNJ6 increases. That is, potassium (K ⁺⁾ a reduced current density to cause pain disorders Chopi leaf extract, quercitrin (quercitrin) or aching pain diseases potassium (K ⁺⁾ current density processes the jerin (afzelin) due to the increased .

Example 16. Improvement of rheumatoid arthritis in collagen-induced animal model (CIA)

After treating collagen-derived animal models (CIA) with extracts of papaya leaves or active compounds (quatitrin, arthritis), NK cells (natural killer cells) were isolated to measure the expression level of IFN-y cells and the therapeutic effect of rheumatoid arthritis Respectively.

IFN-y is a cytokine produced by T cells or NK cells by immunostimulation, and collagen-induced animals show a tendency to increase the expression of IFN-y cells. Fig. 13 is a graph showing the amount of IFN-y production in NK cells measured after treating a collagen-derived animal model (CIA) with a papaya leaf extract or an active compound (aquatitin, afzelin). According to FIG. 13, it can be confirmed that the expression level of IFN-y in NK cells was significantly reduced in the experimental group treated with extracts of papaya leaf or active compounds (aquatitin, arthritis) in contrast to the collagen-induced animal model (CIA).

Example 17. Improvement of rheumatoid arthritis in collagen-induced animal model (CIA)

IL-17, IL-21 and IL-22 expression levels of T-cell IL-6 and TH17 cells after treatment with extracts of papaya leaf or active compounds (quasitrin, arthritis) in collagen-induced animal model (CIA) And the treatment effect of rheumatoid arthritis was confirmed.

Rheumatoid arthritis is an inflammatory disease involving severe pain in various joints of the human body. There are abundant inflammatory cytokines (IL-6, IL-17, IL-21 and IL-22) in joints of rheumatoid arthritis patients. FIG. 14 is a graph showing the effect of the inflammatory-promoting cytokines (IL-6, IL-17, IL-21 and IL-21) measured after treating the collagen-derived animal model (CIA) 22) expressed in the culture medium. FIG. 14 shows that the experimental group treated with the extract of P. japonicus or the active compound (quasitrin, arthritis) compared to the collagen-induced animal model (CIA) decreased the expression level of IL-6 secreted from T cells, It was confirmed that the expression levels of IL-17, IL-21 and IL-22 secreted were remarkably reduced.

Example 18. Effect of autoimmune therapy

Inhibition of inflammatory-promoting cytokines has been reported to inhibit autoimmune diseases such as atopy. Thus, in this Example, mast cell RBL-2H3 was treated with extracts of papaya leaf or active compounds (quasitrin, arthritis) to confirm secretion inhibition ability of? -Hexosaminidase. In other words, the extract of papaya leaf or the active compounds (quasitrin, arthritis) inhibited the degranulation of mast cells. The results are shown in Table 10 below.

Treatment amount
(μg / mL) Degranulation inhibitory effect (% inhibition rate) Ketotypen Mulberry extract Aquitin Afzelin 100 43.9 ± 1.45 30.8 ± 0.65 22.2 ± 0.32 40.9 ± 0.98 50 32.8 ± 1.04 16.2 ± 0.48 19.8 ± 0.28 41.3 ± 1.67 25 20.2 ± 0.84 12.8 ± 0.39 14.3 ± 0.11 39.4 ± 1.06 12.5 13.8 ± 0.88 2.7 ± 1.20 6.3 ± 0.13 25.1 ± 1.68

Table 10 shows that the detergent inhibitory effect on RBL-2H3 cells is superior to that of ketotifen drugs known as antihistamines. Compared to the ketotifen drug, the extracts showed about 70% inhibition of decarburization, about 50% inhibition of quercitin and 93% inhibition of afzelinen at 100 μg / mL of treatment capacity. Compared with the ketotifen drug, about 63% of the extract of Chrysanthemum japonica extract, about 70% of quercitin, and 195% of 195% of desazurin inhibited the treatment capacity at 25 μg / mL.

[Reference Example]

The present invention is an invention characterized by a pharmaceutical composition or a health food composition based on the pain suppression and anti-inflammatory effect of Zanthoxylum piperitum leaf extract. Korean Patent No. 10-1363311 discloses a therapeutic and preventive effect of ulcerative colitis of Zanthoxylum schinifolium extract.

It is judged that the first and second trees are belonging to Zanthoxylum sp. And can be treated as the same or similar plants. In this reference example, it is verified from the results of various analyzes that the leaf extract of Zanthoxylum piperitum and the fruit extract of Zanthoxylum schinifolium are distinct extracts having substantially different contents.

(1) GC-MS analysis of the leaf extracts and the fruit extracts of Sancho

The extracts of Zanthoxylum piperitum and Zanthoxylum schinifolium were extracted with a 90% aqueous ethanol solution. The extracts were analyzed by GC-MS. In Table 11, GC-MS analysis of the leaf extract and anthocyanin extract of chinese cabbage is summarized.

division ingredient Relative content (%) Leaf leaf extract Anthocyanin extract RT Area RT Area One 2- (2-methyl-12-propen-1-yl) 5.994 0.2 2 Benzothiazole 9.406 2.87 3 2-undecanone 10.59 0.61 4 2-butenal 11.8 1.02 5 1-Diterio methyloctane 12.96 0.74 6 Pent-2-enoic acid ethyl ester 13.05 1.78 7 1 H -1,2,4-triazole 13.75 0.54 8 2-tridecanone 14.24 22.97 9 phenol 14.54 1.42 10 Hexanoy 15.02 1.43 11 3- t -Butyl-1-methyl-2-hypazolin-5-one 15.68 0.36 12 2,6-octadiene-1-ol, 3,7-dimethylacetate 15.84 0.63 13 Cariopilene 15.92 0.4 14 ( trans ) -2-azidocyclopentan-1-ol 15.99 0.84 15 Methyl-beta- d -galactopyranoside 16.57 1.07 16 Decanoic acid 16.65 1.53 17 Tridecan 17.27 1.53 18 2-pentadecanone 17.58 15.5 19 Hydroxy-alpha-terphenylacetate 2,6-dimethyl-3,5,7-octatrien-2-ol 18.58 0.55 20 (-) - Ranolide 18.78 1.3 21 7 H -furo [3,2- g ] -benzopyran-7-one 19.7 3.93 22 Solareen 19.74 6.43 23 Caffeine 19.92 3.51 24 1-8-methadiene-4-ol 20.14 0.54 25 2-hexadecen-1-ol 20.32 0.88 26 2-Dodecanone 20.6 0.64 27 Hexadecanoic acid 20.94 1.77 28 Dimethyl-3- (4-hydroxyphenyl) octa- 1 21.06 0.74 29 (4,4-dimethyl-2,4,5,6-tetrahydro- 1H -inden-2-yl) acetic acid 21.45 0.77 30 1,2-benzenedicarboxylic acid 21.51 0.53 31 Octadecanoic acid 21.88 0.67 32 Isopropylphenylacetate 21.93 1.03 33 3,7,11-Trimethyl-2,4,10-dodecatrien-1-ol 22.14 2.23 34 7 H -furo [3,2- g ] -benzopyran-7-one-4-methoxy 22.94 1.04 35 Ethyl linoleate 23.24 0.44 36 Ethyl 9,12,15-octadecatrienoate 23.33 1.38 37 2-hexadecen-1-ol 23.48 2.04 38 4 H -cyclopenta [ c ] furan 24.1 2.27 39 Cyclohexene 24.19 0.76 40 4,5-dihydro-3-ethyl-5-methyl-1,2,4-triazine 24.3 0.58 41 Neoheurcurin benzene acetic acid 24.45 2.05 42 Neoheururic cyclopentanecarboxylic acid 24.53 1.22 43 7,11,15-trimethyl, 3-methylene-1-hexadecene 26.44 0.22 44 7 H- furo [3,2- g ] [1] benzopyran-7-one 26.56 0.78 45 3- (4-fluoro-3-methylphenyl) propylamine 27.47 0.32 46 1-Methyl-2- (indol-3'-yl) -benzimidazole 28.21 1.08 47 Propane, 1- (benzyloxy) -2,3-epoxy 28.5 1.43 48 1,2-benzenedicarboxylic acid 28.67 1.2 49 2,6,9,11-dodecatetranine-1-carboxylic acid 28.69 0.24 50 1,4-cyclooctadiene, 6-bromo 28.81 0.75 51 9-amino -6 H - benzo [c] chromen -8,10- dicarboxylic I Trill 28.88 1.34 52 Hexadecanoic acid 28.93 0.75 53 1- (1'-methoxycyclopropyl) -6,6-dimethyl-2,4-cyclooctadiene- 29.49 0.44 54 Hexadecanoic acid, ethyl ether 29.58 0.34 55 2-Cyclohexene-1-carboxaldehyde 29.67 0.71 56 4,6-dimethylindan 30.96 8.56 57 2,2-ditotheriobenz [b] quinuclidine 31.67 11.02 58 9,10 H- 9-cyanophenanthrene 32.04 3.62 59 Neoherculin 5- (propen-2-yl) -1,3,7-nonatriene 32.85 6.49 60 Piperidinyl- (1-oxopropyl) - (cas) < / RTI > 33.03 1.29 61 5,5 '- (tetrahydro-1 H , 3 H- furo [3,4- c ] furan-1,4-diyl) bis-1,3-benzodioxole 34.77 1.67 62 5,5 '- (Tetrahydro-1 H , 3 H- furo [3,4- c ] furan-1,4-diyl) -bis-1,3-benzodioxole- 34.84 4.11 63 (1 R ) - (-) - 35.24 22.12 64 Methyl-3- (prop-2'-en-1-yl) pyrrolidin- 35.4 6.92 65 2-propanone-1-hydroxy-1-phenyl 35.68 17.78 66 a-acetyl-benzyl alcohol 35.74 3.91 67 Benzene, 1-methoxy-4-octyl 36.07 0.98 68 2- (3-carbomethoxyphenyl) -1,3-dioxolane 36.76 1.6 69 Benzene, 1-cyclopropylmethyl-4- (1-methylethyl) 37.45 0.4 70 Alpha-Gui I 37.56 0.44 71 Cyclopentanecarboxylic acid 37.94 0.66 72 1-ol, 4-chloro-2-methyl-1-phenyl-acetylphenylcarbinol 38.36 0.55 73 Bis ( p -phenoxyphenyl) -7- (3,4-methylenedioxy) -tetrahydrobenzofuranone 41.25 0.41 74 Sesamin 5,5 '- (tetrahydro-1- H , 3H - furo [3,4- c ] furan- 47.56 0.21 75 Indole, 5-methyl-2-phenyl-2-ethylacridine 48.42 0.35 76 Stigmast-5-en-3-ol 49.78 0.71

As shown in Table 11 above, leaf extract of Zanthoxylum piperitum and Zanthoxylum schinifolium ) have almost no common components, and it can be confirmed that the compositions of the components contained therein are remarkably different.

In order to examine the analgesic effect of peripheral nervous system and central nervous system simultaneously on leaf extract, fruit extract and zanthoxylum schinifolium fruit extract of Zanthoxylum piperitum , analgesic efficacy was measured by the formalin test method, Are shown in Table 12 below.

Comparison of analgesic efficacy of chestnut leaf, fruit and anchovy extract Test group Dosage Concentration (mg / kg) % Inhibition 1 phase 2 phase Control group CMC 0.5% - - Acetaminophen 100 35.2 41.7 Chopped leaf 100 35.2 22.6 Cherry fruit 100 16.6 10.8 Anthocyanin 100 14.9 15.5

According to the following Table 12, it can be confirmed that the extract of Peppermint Leaf is remarkably superior to the extract of Peppermint Fruit or Peppermint Fruit Extract.

[Formulation Example]

Examples of the preparation of a pharmaceutical composition or a health food composition containing the extract, fraction or active compound (quercitrin and afzelin or a mixture thereof) of the present invention as an active ingredient were described in the following formulation examples. The following Preparation Examples are intended to illustrate the present invention in detail, but the present invention is not limited thereto.

Formulation Example 1. Preparation of a pharmaceutical composition

(1) Preparation of tablets

After dissolving 10 g of povidone in 50 g of ethanol to prepare a binding solution, 150 g of the active ingredient was added to the binding solution and homogeneously stirred. 130 g of silicified microcrystalline cellulose, 15 g of croscarmellose sodium, and 20 g of colloidal silicon dioxide were mixed, and then a binding solution homogeneously stirred with the active ingredient was added thereto, followed by granulation, followed by drying and sizing of the granules. 15 g of crospovidone was added to the prepared granules, and the mixture was mixed. 3.5 g of colloidal silicon dioxide and 6.5 g of magnesium stearate were added thereto, and the mixture was subjected to a filtration step, followed by purification.

(2) Production of tablets

After dissolving 19 g of povidone in 50 g of ethanol to prepare a binding solution, 150 g of the active ingredient was added to the binding solution and homogeneously stirred. 143 g of microcrystalline cellulose, 15 g of croscarmellose sodium, and 20 g of neosilane were mixed and then stirred to homogeneously mix with the active ingredient. The mixture was granulated and dried and dried. 15 g of crospovidone was added to the granules and mixed. 5 g of colloidal silicon dioxide and 8 g of magnesium stearate were added, and the mixture was subjected to a filtration process to form tablets.

(3) Preparation of tablets

After dissolving 12.5 g of povidone in 50 g of ethanol to prepare a binding solution, 150 g of the active ingredient was added to the binding solution and homogeneously stirred. 62.5 g of silicified microcrystalline cellulose, 65 g of lactose hydrate, 15 g of croscarmellose sodium, and 20 g of colloidal silicon dioxide were mixed and the mixture was homogenously mixed with the active ingredient to give a granulation process, followed by drying and sizing of the granules Respectively. 15 g of crospovidone was added to the prepared granules, and the mixture was mixed. 3.5 g of colloidal silicon dioxide and 6.5 g of magnesium stearate were added thereto, and the mixture was subjected to a filtration step, followed by purification.

(4) Preparation of tablets

After 19 g of povidone was dissolved in 33.5 g of ethanol to prepare a binding solution, 150 g of the active ingredient was added to the binding solution and stirred homogeneously. 105 g of silicified microcrystalline cellulose (amount of silicified microcrystalline cellulose is added by the amount of ethanol contained in the main component), 17.5 g of croscarmellose sodium and 20 g of neohelin are mixed and homogeneously stirred with the active ingredient After the granulation process was carried out, the granules were dried and set. 17.5 g of crospovidone and 33 g of silicified microcrystalline cellulose were added to the prepared granules, and 7.5 g of colloidal silicon dioxide and 8 g of magnesium stearate were added thereto, followed by filtration and purification.

(5) Manufacture of coating definition

755 mg of the tablets prepared in Preparation Examples 1 to 4 (including 300 mg of the active ingredient) were coated with a conventional pen coating system ( ^Opadry® , Opadry ^200® or ^Opaglos® )

Preparation Example 2. Preparation of health food

(1) Production of beverages

1000 mg of active ingredient, 1000 mg of citric acid, 100 g of oligosaccharide and 1 g of taurine were mixed, and purified water was added thereto to make the total volume 900 ml. After stirring and heating at 85 DEG C for about 1 hour, the solution was filtered and sterilized by sealing in a sterilized 2 liter container to prepare a beverage.

[Experimental Example]

Experimental Example 1. Determination of the Disintegration of Tablets

Twelve of 755 mg tablets (containing 300 mg of active ingredient) prepared in Preparation Example 5 were prepared. The test was conducted according to the pharmacodynamic disintegration test method to confirm the number of disintegrated tablets at intervals of 5 minutes, and the results are shown in Table 13 below. The test was run until the 12 tablets were completely disintegrated.

Test group Number of disintegrated tablets 5 minutes 10 minutes 15 minutes Tablets of Formulation Example 5 0 Three 9

Experimental Example 2 Measurement of wear on the pad

755 mg tablets (containing 300 mg of the active ingredient) prepared in Preparation Example 5 were divided into tablets having a hardness of 10 to 12 kp, 12 to 14 kp, and 14 kp or more. As a result of measuring the degree of grindability of the tablets, the degree of grindability was 0.1% or less at a hardness of 10 kp or more.

Experimental Example 3 Measurement of Physical Properties of Tablets

The bulk density, the tapped density, the Hausner ratio, and the compressibility index of the tablet 755 mg (including 300 mg of the active ingredient) prepared in Preparation Example 5 were measured to determine the fluidity. ), And the angle of repose (Angle of repose). The results are shown in Table 14 below.

division Tablets of Formulation Example 5 Bulk density 0.501 Tap density 0.547 Houseboar 1.093 Compression index 8.500 Angle of repose ( ^o ) 38.0

Claims (20)

The extracts of Zanthoxylum piperitum leaves with at least one solvent selected from the group consisting of C _{1 -4} alcohols and aqueous C _{1 -4} alcohols, comprising quercetin-3-O-alpha-L- Laminoside or camphorol-3-O-alpha-L-lambsoside represented by the following formula (2) or a mixture thereof is contained as an active ingredient.
[Chemical Formula 1]

(2)

The method according to claim 1,
Wherein the solvent used for the extraction is an aqueous 90 to 95% ethanol solution.
A pharmaceutical composition for treating or preventing inflammation or pain, comprising the ethyl acetate fraction obtained by extracting the Zanthoxylum piperitum extract of claim 1 with ethyl acetate.
4. The method according to any one of claims 1 to 3,
The Zanthoxylum piperitum or ethyl acetate fraction contains at least one compound selected from the group consisting of 4'-hydroxy-acetophenone, 2,4-di- tert -butylphenol and 1,2-benzenedicarboxylic acid as active ingredients Or a pharmaceutically acceptable salt thereof.
3-O-alpha-L-rhamnoside represented by the following formula (1), camphorol-3-O-alpha-L-lamboside represented by the following formula (2) A pharmaceutical composition for the treatment and prevention of inflammation or pain.
[Chemical Formula 1]

(2)

6. The method of claim 5,
4-hydroxy-acetophenone, 2,4-di- tert -butylphenol, and 1,2-benzenedicarboxylic acid. ≪ / RTI >
6. The method according to any one of claims 1 to 3, 5 and 6,
Wherein said inflammation is arthritis.
8. The method of claim 7,
Wherein said arthritis is rheumatoid arthritis or degenerative arthritis.
6. The method according to any one of claims 1 to 3, 5 and 6,
A pharmaceutical composition for treating or preventing inflammation or pain, characterized by being formulated in tablet form.
A herbal extract obtained by extracting Zanthoxylum piperitum leaves with at least one solvent selected from the group consisting of C _{1 -4} alcohols and C _{1 -4} alcohols, quercetin-3-O-alpha-L- Side or camphorol-3-O-alpha-L-lambsoside represented by the following formula (2) or a mixture thereof is contained as an active ingredient.
[Chemical Formula 1]

(2)

11. The method of claim 10,
Wherein the solvent used for the extraction is a 90 to 95% aqueous solution of ethanol.
A health food composition for improving inflammation or pain comprising an ethyl acetate fraction obtained by extracting Zanthoxylum piperitum extract of claim 10 with ethyl acetate.
13. The method according to any one of claims 10 to 12,
The extract or ethyl acetate fraction of Zanthoxylum piperitum may contain, as active ingredient, one kind selected from the group consisting of 4'-hydroxy-acetophenone, 2,4-di- tert -butylphenol and 1,2-benzenedicarboxylic acid Or a pharmaceutically acceptable salt or solvate thereof.
3-O-alpha-L-rhamnoside represented by the following formula (1), camphorol-3-O-alpha-L-lamboside represented by the following formula (2) A health food composition for improving inflammation or pain.
[Chemical Formula 1]

(2)

15. The method of claim 14,
Wherein at least one compound selected from the group consisting of 4'-hydroxy-acetophenone, 2,4-di- tert -butylphenol, and 1,2-benzenedicarboxylic acid is further contained. ≪ / RTI >
15. A method according to any one of claims 10 to 12, 14 or 15,
Wherein the inflammation is arthritis.
I) extracting a leaf of Zanthoxylum piperitum with at least one extraction solvent selected from the group consisting of C _1-4 alcohol and C _1-4 alcohol aqueous solution to obtain an alcoholic extract;
Ii) suspending the alcohol extract in water, and subsequently fractionating the mixture with normal hexane, dichloromethane, ethyl acetate and normal butanol to obtain an ethyl acetate fraction; And
Iii) The ethyl acetate fraction was subjected to silica gel column chromatography and medium pressure chromatography (MPLC) to obtain quercetin-3-O-alpha-L-rhamnoside represented by the following formula 1 or camphor- -O-alpha-L-rhamnoside, respectively;
≪ / RTI >
[Chemical Formula 1]

(2)

18. The method of claim 17,
Wherein the solvent used for the extraction in step i) is a 90 to 95% aqueous solution of ethanol.
18. The method of claim 17,
Wherein the extraction in step i) is carried out at a temperature of 20 to 80 ° C.
18. The method of claim 17,
Further comprising the step of removing the emulsion by centrifuging the alcohol extract obtained in the step i).

Images